[go: up one dir, main page]

WO2010038974A3 - 이뮤노글로블린 에이 신증과 티지비엠 신증의 진단용 조성물 및 키트 - Google Patents

이뮤노글로블린 에이 신증과 티지비엠 신증의 진단용 조성물 및 키트 Download PDF

Info

Publication number
WO2010038974A3
WO2010038974A3 PCT/KR2009/005589 KR2009005589W WO2010038974A3 WO 2010038974 A3 WO2010038974 A3 WO 2010038974A3 KR 2009005589 W KR2009005589 W KR 2009005589W WO 2010038974 A3 WO2010038974 A3 WO 2010038974A3
Authority
WO
WIPO (PCT)
Prior art keywords
nephropathy
tgbm
urine
protein
iga nephropathy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2009/005589
Other languages
English (en)
French (fr)
Other versions
WO2010038974A2 (ko
WO2010038974A9 (ko
Inventor
백문창
문평곤
김용림
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KYUNGBOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
Original Assignee
KYUNGBOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KYUNGBOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION filed Critical KYUNGBOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
Priority to US13/002,224 priority Critical patent/US8927220B2/en
Publication of WO2010038974A2 publication Critical patent/WO2010038974A2/ko
Publication of WO2010038974A3 publication Critical patent/WO2010038974A3/ko
Publication of WO2010038974A9 publication Critical patent/WO2010038974A9/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/5436—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand physically entrapped within the solid phase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/40—Concentrating samples
    • G01N1/4077—Concentrating samples by other techniques involving separation of suspended solids
    • G01N2001/4083—Concentrating samples by other techniques involving separation of suspended solids sedimentation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4713—Plasma globulins, lactoglobulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G01N2333/8121—Serpins
    • G01N2333/8125—Alpha-1-antitrypsin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90287—Oxidoreductases (1.) oxidising metal ions (1.16)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/973—Simultaneous determination of more than one analyte
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/811—Peptides or proteins is immobilized on, or in, an inorganic carrier

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Organic Chemistry (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)

Abstract

본 발명은 타겟 프로테오믹스 기법으로 뇨를 이용한 IgA 신증과 TGBM(thin-glomerular-basement-membrane)의 진단 바이오마커로 사용 될 수 있는 단백질 개발에 관한 것으로서, 정상인의 뇨에서 보다 IgA 신증와 TGBM 신증 환자의 뇨에서 그 양이 증감되어지는 진단 바이오마커 단백질과 이를 이용한 IgA 신증과 TGBM의 진단 및 진행정도를 미리 예견하는 키트에 관한 것이다. 본 발명에 따르면, 사람의 뇨로부터 IgA 신증과 TGBM의 발병여부, 조기진단 및 진행정도를 확인하여 그 증상의 경도를 파악할 수도 있다. 또한 본 발병의 진단 바이오마커 단백질을 기초로 제조된 단일클론항체는 immunoassay 키트(ELISA, antibody coated tube test, lateral-flow test, potable biosensor)에 이용될 수 있을 뿐만 아니라, IgA 신증의 조기진단 및 진행정도를 판단하고, 치료용 목적으로는 신약 개발에 사용되어 질수 있다.
PCT/KR2009/005589 2008-10-01 2009-09-30 이뮤노글로블린 에이 신증과 티지비엠 신증의 진단용 조성물 및 키트 Ceased WO2010038974A2 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/002,224 US8927220B2 (en) 2008-10-01 2009-09-30 Method for diagnosing immunoglobulin A nephropathy and TGBM nephropathy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020080096862A KR100928403B1 (ko) 2008-10-01 2008-10-01 티지비엠 신증의 진단용 조성물 및 키트
KR10-2008-0096862 2008-10-01

Publications (3)

Publication Number Publication Date
WO2010038974A2 WO2010038974A2 (ko) 2010-04-08
WO2010038974A3 true WO2010038974A3 (ko) 2010-08-26
WO2010038974A9 WO2010038974A9 (ko) 2010-11-04

Family

ID=41605396

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/005589 Ceased WO2010038974A2 (ko) 2008-10-01 2009-09-30 이뮤노글로블린 에이 신증과 티지비엠 신증의 진단용 조성물 및 키트

Country Status (3)

Country Link
US (1) US8927220B2 (ko)
KR (1) KR100928403B1 (ko)
WO (1) WO2010038974A2 (ko)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8932808B1 (en) 2004-01-21 2015-01-13 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for determining a graft tolerant phenotype in a subject
JP2008537875A (ja) 2005-03-14 2008-10-02 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 固形臓器移植レシピエントにおいて移植片生着を評価するための方法および組成物
USRE46843E1 (en) 2005-03-14 2018-05-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for evaluating graft survival in a solid organ transplant recipient
US20110201519A1 (en) 2008-08-18 2011-08-18 Sarwal Minnie M Methods and Compositions for Determining a Graft Tolerant Phenotype in a Subject
WO2010083121A1 (en) 2009-01-15 2010-07-22 The Board Of Trustees Of The Leland Stanford Junior University Biomarker panel for diagnosis and prediction of graft rejection
CA2782803C (en) 2009-12-02 2020-09-01 The Board Of Trustees Of The Leland Stanford Junior University Biomarkers for determining an allograft tolerant phenotype
EP2550371A4 (en) 2010-03-25 2013-11-20 Univ Leland Stanford Junior PROTEIN AND GENE BIOMARKERS FOR EXTRACTING ORGAN TRANSPLANTS
WO2012112955A2 (en) 2011-02-17 2012-08-23 The Trustees Of Columbia University In The City Of New York Methods for identifying subjects with a genetic risk for developing iga nephropathy
US8962261B2 (en) 2011-04-06 2015-02-24 The Board Of Trustees Of The Leland Stanford Junior University Autoantibody biomarkers for IGA nephropathy
JP5777149B2 (ja) * 2011-04-27 2015-09-09 国立大学法人 宮崎大学 糸球体濾過膜の異常に関連した疾患の検査方法、およびこれに使用するための検査用キット
WO2014018851A1 (en) * 2012-07-26 2014-01-30 Joslin Diabetes Center, Inc. Predicting and treating diabetic complications
HK1207155A1 (en) * 2012-08-03 2016-01-22 阿斯图特医药公司 Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US10202647B2 (en) 2013-04-12 2019-02-12 The Trustees Of Columbia University In The City Of New York Mutations in DSTYK cause dominant urinary tract malformations
DK3469372T3 (da) 2016-06-10 2023-06-06 Univ Warszawski Medyczny Fremgangsmåder til diagnose og overvågning ved hjælp af urinproteiner som markører i iga-nefropati
WO2018129056A1 (en) 2017-01-04 2018-07-12 The Research Foundation For The State University Of New York Biomarker detection device
PL3358355T3 (pl) 2017-02-04 2024-04-08 Warszawski Uniwersytet Medyczny Zastosowanie surowiczych peroksyredoksyn dwucysteinowych (2-Cys-PRDX) jako biomarkerów przewlekłej choroby nerek (PChN, ang. CKD) takiej jak toczniowe zapalenie nerek (LN), nefropatia IgA (IgAN) i autosomalna dominująca wielotorbielowatość nerek (ADPKD) użytecznych do diagnozowania tych chorób i sposoby różnicowania tych chorób
WO2021152370A1 (en) 2020-01-31 2021-08-05 Warszawski Uniwersytet Medyczny Method of screening for a chronic kidney disease or glomerulopathy, method of monitoring a response to treatment of a chronic kidney disease or glomerulopathy in a subject and a method of treatment of a chronic kidney disease or glomerulopathy
EP4097481A1 (en) 2020-01-31 2022-12-07 Warszawski Uniwersytet Medyczny Method of differentiating of a chronic kidney disease or glomerulopathy, method of monitoring a response to treatment of a chronic kidney disease or glomerulopathy in a subject and a method of treatment of a chronic kidney disease or glomerulopathy
CN114324887B (zh) * 2021-10-14 2025-03-25 深圳市陆为生物技术有限公司 免疫球蛋白a肾病t细胞诊断标志物
WO2024225457A1 (ja) * 2023-04-26 2024-10-31 オリエンタル酵母工業株式会社 ＩｇＡ腎症の判定方法
WO2025045894A1 (en) * 2023-08-28 2025-03-06 Institut National de la Santé et de la Recherche Médicale Methods and kits for diagnosing cause of nephrotic syndrome and guiding therapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998024899A1 (en) * 1996-12-05 1998-06-11 Kyowa Hakko Kogyo Co., Ltd. IgA NEPHROPATHY-ASSOCIATED GENE
WO2000078788A1 (en) * 1999-06-24 2000-12-28 Gene Logic, Inc. NOVEL cDNA ASSOCIATED WITH RENAL DISEASE
WO2007082586A1 (en) * 2006-01-20 2007-07-26 Mosaiques Diagnostics And Therapeutics Ag Method and markers for the diagnosis of renal diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838634B2 (en) * 2005-04-15 2010-11-23 Van Andel Research Institute Methods for measuring glycan levels of proteins
TWI338779B (en) * 2005-07-21 2011-03-11 Academia Sinica Methods,compositions and systems for assaying at least one target analyte in a sample
EP3181705A1 (en) * 2008-11-12 2017-06-21 Caris Life Sciences Switzerland Holdings GmbH Methods and systems of using exosomes for determining phenotypes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998024899A1 (en) * 1996-12-05 1998-06-11 Kyowa Hakko Kogyo Co., Ltd. IgA NEPHROPATHY-ASSOCIATED GENE
WO2000078788A1 (en) * 1999-06-24 2000-12-28 Gene Logic, Inc. NOVEL cDNA ASSOCIATED WITH RENAL DISEASE
WO2007082586A1 (en) * 2006-01-20 2007-07-26 Mosaiques Diagnostics And Therapeutics Ag Method and markers for the diagnosis of renal diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
UEDA, T. ET AL.: "Quantitative analysis of glomerular type IV collagen alpha 3-5 chain expression in children with thin basement membrane disease.", NEPHRON, vol. 92, no. 2, October 2002 (2002-10-01), pages 271 - 278 *

Also Published As

Publication number Publication date
KR100928403B1 (ko) 2009-11-26
WO2010038974A2 (ko) 2010-04-08
US20110236913A1 (en) 2011-09-29
US8927220B2 (en) 2015-01-06
WO2010038974A9 (ko) 2010-11-04

Similar Documents

Publication Publication Date Title
WO2010038974A3 (ko) 이뮤노글로블린 에이 신증과 티지비엠 신증의 진단용 조성물 및 키트
WO2007092627A3 (en) Detection of cancer by elevated levels of bcl-2
JP6666916B2 (ja) 腎疾患の検査方法
NO20076656L (no) Forbedrede immunoassay metoder
CN111183360A (zh) 同时评估非酒精性脂肪性肝炎和肝纤维化状态的生物标志物组合
JP2008529008A5 (ko)
AR063125A1 (es) Ensayo elisa para la deteccion de vegf
JP6608407B2 (ja) 腎疾患バイオマーカー
WO2010057184A3 (en) Methods for detection of acute kidney injury in humans
JP2010522699A5 (ko)
WO2008131261A3 (en) Peptide biomarkers of cardiovascular disease
CN104871004A (zh) 急性肾损伤
JP4197180B2 (ja) 検体中の内分泌物質測定方法
FI3356826T3 (fi) Gdf-15 melanooman diagnostisena markkerina
WO2009016734A1 (ja) 軽度認知機能障害の検定方法
JP5857385B2 (ja) Ａｐｅ１／ｒｅｆ−１を含有する膀胱癌診断用組成物、及びこれを利用した膀胱癌診断キット
JP2011516840A5 (ko)
JP2023511591A (ja) 腸管バリア機能障害および／または肝硬変の検出
WO2008067006A3 (en) A method for quantitative detection of diabetes related immunological markers
WO2007084570A3 (en) High sensitivity secretagogin assays and their uses for diagnosis and/or prognosis
CA2796384A1 (en) A biomarker for renal function in patients with type 2 diabetes
US12398202B2 (en) Use of ITIH1 as biomarker for detection of insulin resistance in diseases accompanied by impaired glucose tolerance
WO2005074461A3 (en) Kits and methods for autoantibody detection
US20160161489A1 (en) Urine-based immuncassay for urocirtub 3 abd duagbisus if skeeo aobea
RU2007137618A (ru) Способ определения степени тяжести послеродовых гнойно-септических заболеваний

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09817984

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13002224

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 09817984

Country of ref document: EP

Kind code of ref document: A2